b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">31945385</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>07</Month>\n            <Day>02</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1873-7064</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>166</Volume>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>04</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Neuropharmacology</Title>\n                <ISOAbbreviation>Neuropharmacology</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Cholinergic modulation inhibits cortical spreading depression in mouse neocortex through activation of muscarinic receptors and decreased excitatory/inhibitory drive.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>107951</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0028-3908(20)30017-4</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuropharm.2020.107951</ELocationID>\n            <Abstract>\n                <AbstractText>Cortical spreading depression (CSD) is a wave of transient network hyperexcitability leading to long lasting depolarization and block of firing, which initiates focally and slowly propagates in the cerebral cortex. It causes migraine aura and it has been implicated in the generation of migraine headache. Cortical excitability can be modulated by cholinergic actions, leading in neocortical slices to the generation of rhythmic synchronous activities (UP/DOWN states). We investigated the effect of cholinergic activation with the cholinomimetic agonist carbachol on CSD triggered with 130\xc2\xa0mM KCl pulse injections in acute mouse neocortical brain slices, hypothesizing that the cholinergic-induced increase of cortical network excitability during UP states could facilitate CSD. We observed instead an inhibitory effect of cholinergic activation on both initiation and propagation of CSD, through the action of muscarinic receptors. In fact, carbachol-induced CSD inhibition was blocked by atropine or by the preferential M1 muscarinic antagonist telenzepine; the preferential M1 muscarinic agonist McN-A-343 inhibited CSD similarly to carbachol, and its effect was blocked by telenzepine. Recordings of spontaneous excitatory and inhibitory post-synaptic currents in pyramidal neurons showed that McN-A-343 induced overall a decrease of the excitatory/inhibitory ratio. This inhibitory action may be targeted for novel pharmacological approaches in the treatment of migraine with muscarinic agonists.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Zerimech</LastName>\n                    <ForeName>Sarah</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universit\xc3\xa9 C\xc3\xb4te d\'Azur, Valbonne-Sophia Antipolis, France; CNRS UMR7275, Institute of Molecular and Cellular Pharmacology (IPMC), Valbonne-Sophia Antipolis, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chever</LastName>\n                    <ForeName>Oana</ForeName>\n                    <Initials>O</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universit\xc3\xa9 C\xc3\xb4te d\'Azur, Valbonne-Sophia Antipolis, France; CNRS UMR7275, Institute of Molecular and Cellular Pharmacology (IPMC), Valbonne-Sophia Antipolis, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Scalmani</LastName>\n                    <ForeName>Paolo</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>U.O. VII Clinical Epileptology and Experimental Neurophysiology, Foundation IRCCS Neurological Institute Carlo Besta, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pizzamiglio</LastName>\n                    <ForeName>Lara</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universit\xc3\xa9 C\xc3\xb4te d\'Azur, Valbonne-Sophia Antipolis, France; CNRS UMR7275, Institute of Molecular and Cellular Pharmacology (IPMC), Valbonne-Sophia Antipolis, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Duprat</LastName>\n                    <ForeName>Fabrice</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universit\xc3\xa9 C\xc3\xb4te d\'Azur, Valbonne-Sophia Antipolis, France; CNRS UMR7275, Institute of Molecular and Cellular Pharmacology (IPMC), Valbonne-Sophia Antipolis, France; Inserm, Valbonne-Sophia Antipolis, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mantegazza</LastName>\n                    <ForeName>Massimo</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universit\xc3\xa9 C\xc3\xb4te d\'Azur, Valbonne-Sophia Antipolis, France; CNRS UMR7275, Institute of Molecular and Cellular Pharmacology (IPMC), Valbonne-Sophia Antipolis, France; Inserm, Valbonne-Sophia Antipolis, France. Electronic address: mantegazza@ipmc.cnrs.fr.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>01</Month>\n                <Day>13</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Neuropharmacology</MedlineTA>\n            <NlmUniqueID>0236217</NlmUniqueID>\n            <ISSNLinking>0028-3908</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Acetylcholine</Keyword>\n            <Keyword MajorTopicYN="Y">Aura</Keyword>\n            <Keyword MajorTopicYN="Y">Carbachol</Keyword>\n            <Keyword MajorTopicYN="Y">Excitation</Keyword>\n            <Keyword MajorTopicYN="Y">Inhibition</Keyword>\n            <Keyword MajorTopicYN="Y">Migraine</Keyword>\n            <Keyword MajorTopicYN="Y">Spreading depolarization</Keyword>\n            <Keyword MajorTopicYN="Y">UP-DOWN states</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>05</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2020</Year>\n                <Month>01</Month>\n                <Day>06</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2020</Year>\n                <Month>01</Month>\n                <Day>09</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>1</Month>\n                <Day>17</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>1</Month>\n                <Day>17</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>1</Month>\n                <Day>17</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31945385</ArticleId>\n            <ArticleId IdType="pii">S0028-3908(20)30017-4</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.neuropharm.2020.107951</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'